Objective
To report the efficacy of subconjunctival bevacizumab injection in patients with corneal neovascularization (NV).
Methods
This retrospective interventional case study included two eyes of two patients with corneal NV due to aqueous-deficient dry
eye with filamentary keratitis in the first case, and corneal graft failure in the second case. Patients received a subconjunctival
injection of 2.5 mg (0.1 ml) bevacizumab. Morphologic changes were investigated by slit-lamp biomicroscopy and corneal photography.
Results
Corneal NV was dramatically regressed a week after injection in the first case. In the second case, minor vessels were regressed
while the major one did not. No infection or inflammation was observed. No relapse was seen within the follow-up of two to
three months.
Conclusion
Subconjunctival injection of bevacizumab may offer an additional strategy for the treatment of corneal NV.
Keywords Bevacizumab - Corneal neovascularization